Penmenvy combines the antigenic components of GSK’s approved Bexsero and Menveo meningococcal vaccines to target five common invasive meningococcal disease (IMD)-causing serotypes (A, B, C, W and Y).

1 GSK’s MenABCWY vaccine combines the antigenic components of the Company’s two well-established meningococcal vaccines—Bexsero (Meningococcal Group B Vaccine) and Menveo (Meningococcal [Groups A, C, ...

with a safety profile consistent with Bexsero and Menveo. GSK’s chief scientific officer, Tony Wood, said that the results show the vaccine protects against “the broadest panel of circulating ...

About MENVEO (Meningococcal [Groups A, C, Y, and W-135] Oligosaccharide Diphtheria CRM 197 Conjugate Vaccine) GSK’s MenACWY vaccine has received regulatory approval in over 60 countries ...

1 Tony Wood, Chief Scientific Officer at GSK, said: “We welcome this positive ... Important Safety Information for MENVEO in the US The following is based on the US Prescribing Information ...

GSK said Penmenvy, which combines components of its Bexsero and Menveo vaccines, could improve vaccination rates by reducing the number of injections required. It is expected to be available in ...